Kenneth Kwok

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 395 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy · 2019 · 320 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados et al. · Annals of the Rheumatic Diseases · 2022 · 204 citations · Full text

Medicine, Cardiology, Pharmacology +17

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

Christina Charles‐Schoeman, Pierre Wicker, Miguel Á. González‐Gay et al. · Seminars in Arthritis and Rheumatism · 2016 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ascorbic acid inhibits ROS production, NF-?B activation and prevents ethanol-induced growth retardation and microencephaly

Kenneth Kwok, Pengfei Yang, Sophia Ng et al. · Neuropharmacology · 2005 · 119 citations

Life Sciences, Neuroscience, Pharmacology +9